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Sodium channel-inhibiting drugs 
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based study
Caroline Fairhurst1, Ian Watt1,2, Fabiola Martin2,3, Martin Bland1 & William J. Brackenbury3
Metastasis is the leading cause of cancer-related deaths. Voltage-gated sodium channels (VGSCs) 
regulate invasion and metastasis. Several VGSC-inhibiting drugs reduce metastasis in murine cancer 
models. We aimed to test the hypothesis that patients taking VGSC-inhibiting drugs who developed 
cancer live longer than those not taking these drugs. A cohort study was performed on primary 
care data from the QResearch database, including patients with breast, bowel or prostate cancer. 
Cox proportional hazards regression was used to compare the survival from cancer diagnosis of 
patients taking VGSC-inhibiting drugs with those not exposed to these drugs. Median time to death 
was 9.7 years in the exposed group and 18.4 years in the unexposed group, and exposure to these 
medications significantly increased mortality. Thus, exposure to VGSC-inhibiting drugs associates 
with reduced survival in breast, bowel and prostate cancer patients. This finding is not consistent 
with the preclinical data. Despite the strengths of this study including the large sample size, the 
study is limited by missing information on potentially important confounders such as cancer stage, 
co-morbidities and cause of death. Further research, which is able to account for these confounding 
issues, is needed to investigate the relationship between VGSC-inhibiting drugs and cancer survival.
Metastasis is responsible for 90% of cancer deaths1. Metastatic tumours are rarely curable and there is 
an urgent need to identify new molecular targets and develop novel therapies. Voltage-gated sodium 
channels (VGSCs) regulate electrical excitability and neuronal migration in the central nervous sys-
tem2–8. Aberrant function of VGSCs is a contributing factor in pathologies including epilepsy, cardiac 
arrhythmias, and neuropathic pain9,10. Several commonly prescribed antiepileptic drugs and Class I anti-
arrhythmic drugs are potent VGSC inhibitors9.
VGSCs are also expressed in cells traditionally classed as “non-excitable”, including microglia, astro-
cytes, immune cells, fibroblasts, and cancer cells, regulating motility and invasion11,12. The VGSC-inhibiting 
drugs ranolazine and phenytoin reduce metastasis in preclinical in vivo tumour models13,14. In addition, 
several VGSC-inhibiting drugs, including carbamazepine, flecainide, mexiletine, phenytoin, riluzole, and 
valproate, reduce in vitro cell behaviours associated with metastasis15–18. Furthermore, valproate, which 
is also a histone deacetylase inhibitor, is being studied as a potential adjuvant therapy for advanced 
cancers19–21. Together, these data suggest that VGSCs promote invasion and dissemination of metastatic 
tumour cells, and may represent novel therapeutic targets for slowing/delaying metastasis. Our hypoth-
esis was that use of VGSC-inhibiting drugs before and during a cancer diagnosis may reduce tumour 
invasion and metastasis, thus improving survival. To test this hypothesis, we analysed data from a UK 
cohort of cancer patients comparing mortality of those who had a recorded prescription for a VGSC 
inhibitor prior to their diagnosis with mortality among those who had not. We focused on carcinomas 
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of the breast, bowel and prostate because VGSC expression has been studied extensively in these cancers, 
and they are the most common12,18,22–29.
Results
In total 93,265 patients were followed from their date of cancer diagnosis. There were 5,440 patients in 
the exposed group and 87,825 in the unexposed group (Fig. 1; Table 1). Formal comparisons indicated 
that there were statistically significant differences between the two groups on all available characteristics 
(p < 0.001, except age p = 0.05); however, visual inspection suggests these differences are small.
Overall Survival. Right censoring occurred at the date the patient left the QResearch practice 
(n = 14,714) or at date of last data transfer from the GP practice (n = 49,633). The median length of 
follow-up after diagnosis (to patient’s exit date) was 5.2 years (range 0 days to 33 years). During 658,399 
person-years of follow-up, there were 28,918 deaths: 1,995 (37%) in the exposed group and 26,923 (31%) 
in the unexposed group (Table 2). The median time to death was 9.7 years (95% confidence interval (CI) 
8.8–10.2) in the exposed group and 18.4 years (95% CI 18.1–18.7) in the unexposed group (log-rank test 
statistic 613.0, df = 1, p < 0.001; Fig. 2). The multivariable-adjusted hazard ratio (HR) for death from any 
cause among VGSC-inhibiting drug users, compared to patients who had never used VGSC-inhibitors, 
was 1.42 (95% CI 1.36–1.49, p < 0.001), indicating a statistically significant increased risk of death in the 
exposed group.
The Grambsch and Therneau test indicated potential non-proportionality of hazards for type of can-
cer, age and age squared (p < 0.05). Log-log and scaled Schoenfeld residual plots are in Supplementary 
Fig. 1. A sensitivity analysis removing these variables from the model produced a larger HR for the 
exposed vs. unexposed groups of 1.70 (95% CI 1.62–1.78, p < 0.001). The additional sensitivity analysis 
including ethnicity, alcohol consumption, smoking status and BMI in the list of original covariates (can-
cer type, gender, age and age squared) gave a similar HR of 1.48 (95% CI 1.42–1.55, p < 0.001) and so 
the conclusion did not alter.
All exposed patients had a recorded prescription for a VGSC-inhibiting drug prior to their index 
cancer diagnosis date and almost half (n = 2,480, 46%) also had a prescription dated after their cancer 
diagnosis, indicating continuation of their prescription independent of cancer. There was no statistically 
significant difference in hazard rates between patients who had prescriptions before and after diagnosis 
compared to those who only had prescriptions before (HR 0.98, 95% CI 0.90–1.07, p = 0.66).
Figure 1. Selection of patients for inclusion in the study. Records provided by QResearch included those 
of 100 000 patients with breast, bowel, or prostate cancer. Of these, 9,146 had prescription for a VGSC-
inhibiting drug prior to cancer diagnosis. Following the indicated exclusions, there were 87,825 unexposed 
patients and 5,440 exposed patients.
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To attempt to capture which patients were actively taking a VGSC-inhibiting drug whilst they had 
cancer, we identified patients in the exposed group who had a prescription in the year following their 
diagnosis (n = 2,251, 41%). Findings were similar to the primary result when this group was compared 
with the unexposed group (HR 1.48, 95% CI 1.39–1.59, p < 0.001).
A Cox regression in which the exposed group was restricted to those patients who started their pre-
scriptions at least one year prior to diagnosis (n = 4,795, 88%) yielded an adjusted HR of 1.43 (95% CI 
1.36–1.50, p < 0.001). This analysis aims to exclude patients who may have developed epilepsy as a result 
of brain metastasis and who started antiepileptic medication as a result of metastatic disease in the 12 
months prior to their actual cancer diagnosis.
Characteristic1
Unexposed2 
(n = 87825)
Exposed3 
(n = 5440)
Total 
(n = 93265)
Gender, n (%)
 Male 37684 (42. 9) 2585 (47.5) 40269 (43.2)
 Female 50141 (57.1) 2855 (52.5) 52996 (56.8)
Age
 Mean (SD) 63.5 (13.7) 64 63.9 (12.7) 65 63.5 (13.6)
 Median (min, max) (30, 99) (30, 98) 64 (30, 99)
Ethnicity, n (%)
 White 50588 (57.6) 3330 (61.2) 53918 (57.8)
 Mixed/Multiple ethnic groups 321 (0.4) 15 (0.3) 336 (0.4)
 Asian/Asian British 1095 (1.2) 34 (0.6) 1129 (1.2)
 Black/Black British 1374 (1.6) 43 (0.8) 1417 (1.5)
 Other 208 (0.2) 4 (0.1) 212 (0.2)
 Not recorded/known 34239 (39.0) 2014 (37.0) 36253 (38.9)
Smoking status, n (%)
 Smoker 12547 (14.3) 804 (14.8) 13351 (14.3)
 Non/trivial smoker 46614 (53.1) 2767 (50.9) 49381 (52.9)
 Ex-smoker 23409 (26.7) 1667 (30.6) 25076 (26.9)
 Not recorded/known 5255 (6.0) 202 (3.7) 5457 (5.9)
 Alcohol consumption, n (%)
 Moderate-heavy drinker 6345 (7.2) 363 (6.7) 6708 (7.2)
 Light drinker 18772 (21.4) 1019 (18.7) 19791 (21.2)
 Non/trivial drinker 51037 (58.1) 3519 (64.7) 54556 (58.5)
 Not recorded/known 11671 (13.3) 539 (9.9) 12210 (13.1)
BMI category, n (%)
 Obese 15631 (17.8) 1182 (21.7) 16813 (18.0)
 Overweight 30495 (34.7) 1932 (35.5) 32427 (34.8)
 Normal range 30217 (34.4) 1740 (32.0) 31957 (34.3)
 Underweight 541 (0.6) 40 (0.7) 581 (0.6)
 Not recorded/known 10941 (12.5) 546 (10.0) 11487 (12.3)
Type of cancer4, n (%)
 Breast 41342 (47.1) 2230 (41.0) 43572 (46.7)
 Bowel 21349 (24.3) 1477 (27.2) 22826 (24.5)
 Prostate 25134 (28.6) 1733 (31.9) 26867 (28.8)
Exit status, n (%)
 Died 26923 (30.7) 1995 (36.7) 28918 (31.0)
 Left 14044 (16.0) 670 (12.3) 14714 (15.8)
 Still registered 46858 (53.4) 2775 (51.0) 49633 (53.2)
Table 1. Patient characteristics by VGSC-inhibiting exposure group. 1Differences between groups 
p < 0.001 (except age p = 0.05). 2Breast/bowel/prostate cancer patients not exposed to VGSC-inhibiting 
drugs. 3Cancer patients exposed to VGSC-inhibiting drugs for any duration. 4First instance of one of 
reference cancers.
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Survival Stratified By Cancer Type. Median time to death for patients whose first diagnosis of one 
of the three index cancers was: prostate cancer, 11.2 years (95% CI 10.9–11.5); bowel cancer, 11.9 years 
(95% CI 11.4–12.3); and breast cancer, 24.3 years (95% CI 23.8–24.7). Separate Cox proportional hazards 
models comparing the exposed and unexposed groups within these subgroups gave a HR of 1.64 (95% 
CI 1.51–1.77, p < 0.001) among breast cancer patients; 1.41 (95% CI 1.31–1.52, p < 0.001) among bowel 
cancer patients; and 1.23 (95% CI 1.13–1.33, p < 0.001) among prostate cancer patients (males only so 
gender was omitted as a covariate) (Table 2).
Survival By Level Of Drug Exposure And Drug Type. In total, 1,972 (36%) exposed patients were 
classified in the low exposure group and 3,468 (64%) in the high exposure group. The HR was 1.28 (95% 
CI 1.19–1.39, p < 0.001) when the low exposure group was compared with the unexposed group and 1.50 
(95% CI 1.42–1.59, p < 0.001) when the high exposure group was compared with the unexposed group 
(Table 2). The high exposure group had a HR 1.17 times higher than the low exposure group (95% CI 
1.07–1.28, p = 0.001).
Patients with cancer who were using VGSC-inhibiting medication regularly had a higher risk of death 
than unexposed patients with cancer (HR 1.64, 95% CI 1.54–1.76, p < 0.001), as did non-regular users 
with cancer (HR 1.29, 95% CI 1.21–1.37, p < 0.001).
We stratified patients based on the most common drug they had been prescribed and compared 
each group with the unexposed group in turn: other Class I antiarrhythmic drug (n = 849, HR 1.11, 
95% CI 0.98–1.24, p = 0.09); lamotrigine (n = 166, HR 1.32, 95% CI 0.96–1.82, p = 0.08); carbamaze-
pine (n = 2,727, HR 1.38, 95% CI 1.29–1.47, p < 0.001); phenytoin (n = 719, HR 1.67, 95% CI 1.50–1.86, 
p < 0.001); and valproate (n = 903, HR 1.74, 95% CI 1.56–1.93, p < 0.001) (Table  2). The other drug 
classes consisted of too few individuals to be included in a comparison (topiramate, n = 64; ranolazine, 
n = 9; riluzole, n = 2; lacosamide, n = 1).
Survival From Any Cancer. Of those included in the population for analysis, 3,773 had a diagno-
sis for a different cancer prior to their diagnosis of one of the three index cancers: 312 (6%) in the 
exposed group and 3,461 (4%) in the unexposed group. Mortality from date of first cancer diagnosis 
Unexposed1 (n = 87825) Exposed2 (n = 5440)
Overall survival
 Number of events (deaths), n (%) 26923 (30.7) 1995 (36.7)
 Median time to death, years (95% CI) 18.4 (18.1 to 18.7) 9.7 (8.8 to 10.2)
 Log-rank test statistic, p-value 613.0, df = 1, p < 0.001
 Adjusted analysis, HR (95% CI, p-value)3 1.42 (1.36 to 1.49, p < 0.001)
Survival by type of cancer4 HR (95% CI, p-value)
 Prostate [Unexposed (n = 25134) vs exposed (n = 1733)] 1.23 (1.13 to 1.33, p < 0.001)
 Bowel [Unexposed (n 21349) vs exposed (n = 1477)] 1.41 (1.31 to 1.52, p < 0.001)
 Breast [Unexposed (n = 41342) vs exposed (n = 2230)] 1.64 (1.51 to 1.77, p < 0.001)
Survival by drug exposure5 HR (95% CI, p-value)
 Unexposed (n = 87825) vs low exposed (n = 1972) 1.28 (1.18 to 1.38, p < 0.001)
 Unexposed (n = 87825) vs high exposed (n = 3468) 1.50 (1.42 to 1.59, p < 0.001)
Survival by most common drug prescription HR (95% CI, p-value)
 Unexposed (n = 87825) vs exposed [Class I antiarrhythmic] (n = 849) 1.11 (0.98 to 1.24, p = 0.09)
 Unexposed (n = 87825) vs exposed [Lamotrigine] (n = 166) 1.32 (0.96 to 1.82, p = 0.08)
 Unexposed (n = 87825) vs exposed [Carbamazepine] (n = 2727) 1.38 (1.29 to 1.47, p < 0.001)
 Unexposed (n = 87825) vs exposed [Phenytoin] (n = 719) 1.67 (1.50 to 1.86, p < 0.001)
 Unexposed (n = 87825) vs exposed [Valproate] (n = 903) 1.74 (1.56 to 1.93, p < 0.001)
Table 2. Time to death estimates by group. 1Breast/bowel/prostate cancer patients not exposed to VGSC-
inhibiting drugs. 2Cancer patients exposed to VGSC-inhibiting drugs for any duration. 3All hazard ratios 
(HR; with 95% confidence interval and p-value) compare unexposed and exposed groups. A HR > 1 
indicates exposed group has increased mortality relative to unexposed group. Models are adjusted for cancer 
type, gender, age and age as a quadratic term except model. 4for which cancer type is omitted (gender also 
omitted in the model among prostate cancer patients). 5Low exposure, < 6 months; high exposure, ≥ 6 
months.
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was significantly increased in the exposed group relative to the unexposed group (HR 1.39, 95% CI 
1.33–1.46, p < 0.001).
Discussion
Our results indicate that the survival of breast, bowel, and prostate cancer patients prescribed 
VGSC-inhibiting drugs is significantly reduced compared to cancer patients not taking these drugs. 
These drugs have well-documented safety profiles, reviewed in detail elsewhere30,31. Adjustment for eth-
nicity, BMI, alcohol consumption, and smoking status did not alter this conclusion. The impact of drug 
intake on survival is worse for breast and bowel cancer patients than for prostate cancer patients. It is not 
possible to establish whether this is a cancer-specific effect or is confounded by gender (females account 
for 98% of the breast cancer patients, 46% of bowel cancer patients and 0% of prostate cancer patients). 
The HR for patients with high exposure to the index drugs is larger than for those with low exposure. 
Survival is significantly reduced for patients prescribed carbamazepine, valproate and phenytoin, but not 
for those prescribed lamotrigine or other Class I antiarrhythmics.
Our findings contrast with preclinical studies showing that VGSC inhibition reduces invasion, migra-
tion and metastasis13–18,20,32. A limitation of these preclinical studies is that they have focused on tumour 
cells in isolation without consideration for the potential detrimental effect of VGSC-inhibiting drugs 
on the immune system or drug-drug interaction with chemotherapy33,34. Our results also contrast with 
several recent clinical studies that suggest that valproate may improve outcome in patients with several 
types of cancer19,35,36. The results of these studies are generally accepted to be due to the function of 
valproate as a histone deacetylase inhibitor, rather than as a VGSC inhibitor20,21,37. One major difference 
between our study and the design of these trials is that we included only patients who had started tak-
ing valproate prior to cancer diagnosis, whereas clinical trials typically added valproate as second line 
therapy in patients with advanced disease. We were unable to determine which patients were actively 
taking VGSC-inhibiting medication whilst they had cancer. Therefore, as a best estimate, we identified 
patients who had a recorded prescription in the year following cancer diagnosis, and found that these 
patients still had a significantly increased mortality. However, we did not have access to indication for 
VGSC-inhibiting drug prescriptions or cause of death and further work is required to establish why 
cancer patients exposed to VGSC-inhibiting drugs have a shorter survival time.
Studies in animals have suggested that several VGSC-inhibiting antiepileptic drugs, including pheny-
toin, valproate and carbamazepine, may increase risk of developing certain cancers38, although epidemi-
ological data are conflicting39–41. In addition, no relationship between these drugs and survival of cancer 
patients has previously been reported. Several antiepileptic drugs, including phenytoin and carbamaze-
pine, are potent inducers of hepatic drug-metabolising enzymes33. Indeed, a number of cancer chemo-
therapeutic agents are substrates for enzyme-inducing action of antiepileptic drugs, including phenytoin 
and carbamazepine38. It is therefore possible that the reduced survival of breast, bowel, and prostate can-
cer patients exposed to VGSC-inhibiting drugs identified in our study may be due to reduced bioavail-
ability and efficacy of concurrent chemotherapies as a result of hepatic enzyme induction. However, we 
also found reduced survival of cancer patients taking valproate, which has no reported enzyme-inducing 
activity33. Our data suggest that the suitability of valproate in cancer patients should be studied further.
A weakness of this study is that the estimation of true association may be affected by confounding by 
indication. Epilepsy patients have an increased risk of premature mortality, predominant at younger age 
and shortly after diagnosis, but can also persist for decades after index seizure. For example, all cause 
standardised mortality ratio of 2.2–3.2 and HR of 3.2 have been reported in several cohort studies42–44. 
Although seizures can contribute to mortality, several comorbidities may interact with epilepsy, worsening 
Figure 2. Kaplan-Meier survival curves for unexposed cancer patients (n = 87,714) and those exposed to 
VGSC-inhibiting drugs (n = 5,436). Log-rank test statistic 613.0, df = 1, p < 0.001. The plot is curtailed at 
15 years when around 12% of patients remained in follow-up54.
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outcome, including psychiatric diseases, gynaecological disorders, accidents, and cancer45. It is possible 
that the reduced survival of breast, bowel, and prostate cancer patients exposed to VGSC-inhibiting 
drugs is due to the majority of these patients having epilepsy as their initial diagnosis and a poorer 
general health status46. In addition to epilepsy, the index drugs may also have been prescribed for other, 
unrelated conditions, including bipolar disorder, depression, migraine and chronic pain9. Thus, it is not 
clear whether co-morbidities of patients exposed to these drugs contributed to their reduced survival. 
Finally, it is possible that some patients had epilepsy caused by brain metastases prior to index cancer 
diagnosis. In such cases, prescription of VGSC-inhibiting antiepileptic drugs might seem to be associated 
with reduced survival, although metastasis itself had been the cause. However, survival was still signifi-
cantly decreased in the intervention arm when we tried to control for this by only including patients who 
had been on VGSC-inhibiting drugs starting ≥ 12 months before first cancer diagnosis.
The strength of this prospectively designed cohort study is that it uses primary care data and thus 
contains a large sample size and statistical power. However, there are a number of weaknesses to take 
into consideration, including the use of GP diagnosis codes to identify cancer and death, the use of 
prescription records to identify medication use when non-compliance is possible, and the lack of infor-
mation on cause of death. A further limitation is that the number of cases exposed to VGSC-inhibiting 
drugs was relatively small. In addition, we did not have information on several potential confounders, 
including epilepsy prevalence, reason for VGSC-inhibiting drug prescription, and tumour stage. Finally, 
it was necessary to use overall survival as a surrogate indicator of metastasis because metastasis and cause 
of death are not reliably recorded in general practice data.
In conclusion, we set out to test the hypothesis that breast, bowel and prostate cancer patients who 
had prolonged prescription of VGSC-inhibiting drugs lived longer than those not taking this medication. 
To our surprise our findings indicate the opposite, contrasting with the preclinical data13–18,32. The rea-
sons for this contradiction are not yet clear. Further work is needed to define cancer-specific mortality 
risk by drug type, dosing and duration, controlling for co-morbidity and indication.
Methods
Ethical Approval. This study was approved by the Department of Biology Ethical Review Body at 
the University of York. The methods were carried out in accordance with the approved guidelines. The 
protocol has been published47.
Data Source. The data source was QResearch, a large consolidated UK primary care database derived 
from the pseudonymised health records of > 13 million patients from 754 general practices. QResearch 
holds data from patients who are currently registered with practices as well as patients who may have 
died or left. The database has been validated with other sources of information48–50.
Study Population. An open cohort of patients registered with a QResearch general practice during 
the study period (01/01/98–31/12/13), aged 30 years or older when they joined, and who had a diagnosis 
of breast, bowel, or prostate cancer (referred to as the index cancers) (n = 10,792,824). From this cohort, 
patients who had a recorded prescription for a VGSC-inhibiting drug prior to the earliest diagnosis of 
an index cancer were identified (n = 9,146). A randomly generated sample of 90,854 patients with breast, 
bowel, or prostate cancer who did not have a prescription for a VGSC-inhibiting drug made up the 
unexposed group. A final dataset of 100,000 patients was provided to the authors (Fig. 1).
Data were provided on year of birth, sex, ethnicity, date of entry to the QResearch database, age 
at entry, exit date (earliest of leaving the QResearch practice, death or latest data transfer from GP), 
status at exit date (died, still registered or left), cancer diagnosis, date of diagnosis, date of death, BMI, 
alcohol consumption, smoking status, and prescriptions of the index VGSC-inhibiting drugs (carbamaz-
epine, lacosamide, lamotrigine, phenytoin, ranolazine, riluzole, topiramate, valproic acid/sodium val-
proate, and other Class I antiarrhythmics (disopyramide, flecainide, lidocaine, mexiletine, procainamide, 
propafenone, quinidine)). Cancer diagnoses, ethnicity, alcohol intake, and use of cigarettes/tobacco were 
classified according to Read codes (Supplementary Table 1)51. We had no access to any data on other 
prescriptions, indication for prescriptions, co-morbidities, cancer stage, other treatments or therapies 
received (including cancer treatments such as chemotherapy or radiotherapy), cancer recurrence, or 
cause of death.
We excluded patients registered with QResearch after 31st December 2012 to allow at least one year’s 
follow-up for all patients (n = 861). The earliest dates of cancer diagnosis were much later in the exposed 
group (from 1981) than the unexposed group (from 1940); therefore, we excluded any patient whose 
primary index cancer diagnosis was before 01/01/81 (n = 2,182). Anomalous, incorrect or infeasible 
dates were removed. Dates of cancer diagnosis indicating the patient was < 25 at time of diagnosis were 
excluded.
Potential Confounders. Ethnicity was categorised according to the 2011 UK census. Missing data 
techniques were not implemented; instead, a ‘not recorded/known’ category was used. For potential con-
founders (alcohol, smoking, BMI), the last value recorded prior to cancer diagnosis was used. If a value 
was only recorded after cancer diagnosis then the earliest was taken. Using Read codes, or raw values 
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where the Read code was uninformative, risk factors were categorised as follows: alcohol consumption - 
non/trivial drinker (< 1 unit/day), light drinker (1–2 units/day), moderate-very heavy drinker (3+ units/
day), not recorded/known; smoking status - ex-smoker, non/trivial smoker (< 1 cigarette (or equivalent) 
per day), smoker (1+ cigarette/day), not recorded/known; and BMI – underweight (< 18.5), normal 
range (18.5–24), overweight (25–29), obese (30+ ), not recorded/known.
VGSC-Inhibiting Drug Use. All prescriptions relating to one of the VGSC-inhibiting drugs were 
provided. One-off prescriptions for lidocaine injections were excluded as these were likely used as a local 
anaesthetic and therefore to have a transient effect (n = 3,692). Extent of drug exposure was estimated 
by calculating the time between the first and last recorded prescription. Patients were classified into two 
exposure groups: low (< 6 months, n = 1,972), and high (≥ 6 six months, n = 3,468). In addition, the 
most commonly prescribed class of drug for each patient was identified.
Patients who had at ≥ 2 prescriptions relating to one of the VGSC-inhibiting drugs within 2 years 
before the date of the cancer diagnosis, including at least one within 6 months before were classified as 
regular and recent VGSC-inhibiting drug users (n = 2,153). All other patients exposed to the index drugs 
were classified as non-regular users (n = 3,287)52.
Statistical Analysis. Characteristics of the exposed and unexposed groups are summarised using 
descriptive statistics (mean, SD, median, minimum, maximum) for continuous variables, and count and 
percentage for categorical data. Formal statistical comparisons were made between the two groups using 
a t-test or chi-squared test as appropriate.
Analyses were conducted in Stata v13 using two-sided statistical tests at the 5% significance level. 
Regression models to compare the exposed and unexposed groups were adjusted for type of cancer, 
gender and age at diagnosis (age was included as both a linear and quadratic term (age+ age2)) unless 
otherwise stated. Multivariable-adjusted HRs are presented with 95% CIs and p-values. The distribution 
of time from cancer diagnosis to death (all cause) was described using Kaplan-Meier survival estimates 
for the two groups. The statistical equivalence of the two curves was examined using the log-rank test. 
Survival from cancer diagnosis was compared between the exposed and unexposed groups using Cox 
proportional hazards regression. In a sensitivity analysis, we also included ethnicity, smoking status, 
alcohol consumption and BMI as covariates.
Secondary analyses using separate multivariable-adjusted Cox models compared the survival of the 
unexposed group with cancer with the following subsets of patients from the exposed group with cancer: 
the low exposure group; the high exposure group; regular VGSC users; non-regular VGSC users; patients 
who had at least one prescription in the year following their diagnosis; and, for each drug in turn, 
patients for whom that drug was the most commonly prescribed. We also considered survival stratified 
by cancer type using the same model specification but omitting cancer type as a covariate (and gender 
among prostate cancer patients). For most patients, one of the index cancers was the primary cancer 
diagnosis, but a small number were diagnosed with a different cancer first. We therefore compared sur-
vival from the date of first cancer diagnosis with a Cox model, adjusting for type of cancer (including 
‘Other’ as a category in the cancer type variable), gender, age and age2.
Cox regression models require a number of assumptions to be valid. Firstly, the issue of non-informative 
censoring. Individuals in this study were censored if they left the QResearch practice or their date of last 
data transfer from the GP practice was before death. These mechanisms for censoring are not related to 
the probability of death so the assumption is reasonable. The second key assumption is that the propor-
tional hazards model applies. We used the Grambsch and Therneau test (estat phtest command with the 
detail option in Stata) to assess the proportionality for each predictor and for the model as a whole53. 
In addition, we produced log-log plots (–log(-log(S(t))) against log(time), where S(t) is the survivor 
function at time t) for the categorical predictors, and scaled Schoenfeld residuals against time for the 
continuous factors (age and age squared).
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